Refer to the following important safety details for information on intended use, potential side effects and risks, considerations for specific groups, and possible drug interactions linked to the prescription treatments mentioned.
Reporting Side Effects
Riovie encourages users to promptly report any side effects or adverse reactions to a licensed healthcare provider and the pharmacy that dispensed the medication. To report suspected reactions to these medications, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
For emergencies, call 911 or go to your nearest emergency department.
Advertisements by Riovie
All advertisements from riovie.com are paid for by Riovie and are intended to market Riovie’s services. Some advertisements may feature paid actors or dramatizations. When real Riovie customers or endorsements are included, this will be clearly disclosed. Individual results may vary, and specific outcomes are not guaranteed.
Riovie’s Role
Riovie connects users with licensed healthcare providers for evaluations regarding the suitability of the treatments advertised. It may also assist with prescription coordination through an external pharmacy network.
Riovie acts as a managed services provider and does not offer medical advice, fill prescriptions, or function as a licensed healthcare facility or pharmacy. Instead, it provides technology and administrative support to enable medical consultations and prescription logistics. For further details, see Riovie’s Terms of Service.
Promotional Offers on riovie.com
Occasionally, the website may present promotional pricing or special introductory offers. These promotions are valid for 24 hours after they are removed from the website.
The claim “same price at every dose” is subject to the following:
- Pricing may change at any time due to supply or market conditions at the discretion of riovie.com.
- Any “same price at every dose” promotion expires within 24 hours of any price updates.
- Introductory or promotional pricing, including “first month” offers, are not governed by the “same price per dose” policy and only apply to full-price products as listed on the website.
Prescriptions and Medications
Prescription drugs require evaluation and approval by a qualified healthcare provider, and issuance is solely at the provider’s discretion. Access to treatment plans and medications is not assured.
Prescriptions issued through Riovie may be filled by licensed pharmacies within its affiliated network.
All prescription medications involve potential risks. Please review all associated safety details and consult your provider for personalized advice.
Compounded Drug Formulations
In certain situations, healthcare providers may prescribe compounded medications, which are custom-prepared by licensed compounding pharmacies based in the U.S. These medications are not FDA-approved for safety or effectiveness but may be used when alternatives are not available or appropriate.
Riovie helps facilitate both FDA-approved and compounded medication fulfillment via its partner pharmacy network. These formulations are personalized to meet individual patient requirements and may differ from commercial products.
Trademark Notice
Mounjaro® and Zepbound® are registered trademarks owned by Eli Lilly and Company. Riovie is not affiliated with or endorsed by the manufacturers of any brand-name medications. For further information, visit Eli Lilly’s official website.
Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Riovie is not affiliated with or endorsed by Novo Nordisk A/S, the manufacturer of these medications. For further information, visit Novo Nordisk’s official website.
Contact Information
For any questions about Riovie’s services or advertising content, please reach out to support@riovie.com.
Semaglutide
Important Safety Information Regarding Compounded Semaglutide Products
Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy. Your healthcare provider may prescribe compounded semaglutide based on your medical consultation.
Semaglutide is a GLP-1 receptor agonist used for chronic weight management alongside a reduced-calorie diet and increased physical activity for people with a BMI of:
- 30 kg/m² or greater (obesity), or
- 27 kg/m² or greater (overweight) with at least one weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia).
Do not use semaglutide if:
- You or a family member has had medullary thyroid carcinoma (MTC).
- You have MEN 2 syndrome.
- You’ve had a serious allergic reaction to semaglutide.
Inform your healthcare provider if you:
- Have or had issues with your pancreas, kidneys, or eyes.
- Have a history of depression or mental health issues.
- Are pregnant or breastfeeding.
Serious risks include:
- Thyroid tumors (including cancer)
- Gastroparesis (stomach paralysis)
- Pancreatitis
- Gallbladder issues
- Hypoglycemia (especially with type 2 diabetes)
- Kidney failure
- Serious allergic reactions
- Vision changes
- Increased heart rate
- Depression or suicidal thoughts
Common side effects: nausea, diarrhea, vomiting, stomach pain, headache, tiredness, indigestion, belching, upper respiratory symptoms, severe constipation, bloating, acid reflux, and fatigue. Sublingual delivery specifically increases the risk of oral irritation or a chalky aftertaste, while slightly reducing the intensity of severe, sudden nausea waves.
Administration: Place the tablet completely under your tongue each morning on an empty stomach, letting it dissolve fully for at least two minutes without chewing or swallowing, and avoid eating or drinking anything for 30 minutes afterward.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Tirzepatide
Important Safety Information Regarding Compounded Tirzepatide Products
Compounded tirzepatide is not FDA-approved but may be prescribed legally based on your provider’s assessment.
Tirzepatide is a GIP and GLP-1 receptor agonist used for chronic weight management with lifestyle changes in adults with a BMI of:
- 30 kg/m² or greater (obesity), or
- 27 kg/m² or greater (overweight) with comorbidities such as hypertension, diabetes, dyslipidemia, sleep apnea, or cardiovascular disease.
Do not use tirzepatide if:
- You or a family member has had MTC.
- You have MEN 2 syndrome.
- You’ve had a serious allergic reaction to tirzepatide.
Inform your provider if you:
- Have or had issues with your pancreas, kidneys, stomach, or eyes.
- Have a history of depression or mental health issues.
- Are pregnant or breastfeeding.
Serious risks include:
- Thyroid tumors (including cancer)
- Gastroparesis
- Pancreatitis
- Gallbladder disease
- Hypoglycemia
- Kidney failure
- Allergic reactions
- Vision changes
- Depression or suicidal thoughts
Common side effects: nausea, diarrhea, vomiting, stomach pain, headache, tiredness, indigestion, belching, upper respiratory symptoms, severe constipation, bloating, acid reflux, and fatigue. Sublingual delivery specifically increases the risk of oral irritation or a chalky aftertaste, while slightly reducing the intensity of severe, sudden nausea waves.
Administration: Place the tablet completely under your tongue each morning on an empty stomach, letting it dissolve fully for at least two minutes without chewing or swallowing, and avoid eating or drinking anything for 30 minutes afterward.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
